Trial reportJAMA network open2022
Remdesivir in Patients With Severe Kidney Dysfunction: A Secondary Analysis of the CATCO Randomized Trial.
Trial report in JAMA network open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04330690 (A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO: Canadian Treatments for COVID-19), in Conjunction With the Public Health Emergency SOLIDARITY Trial (World Health Organization)
Who cites it
14 citing papers in PubMed, 29 citations in OpenAlex.
- Article
- Remdesivir in COVID-19: pros and cons.Frontiers in pharmacology · 2026Review
- Long COVID and the kidney.Nature reviews. Nephrology · 2025Review
- Antimicrobial dosing considerations in critically ill patients with acute kidney injury: A review.World journal of nephrology · 2025Review
- Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: network meta-analysis and budget impact analysis.Frontiers in pharmacology · 2025Article
- Safety and effectiveness of remdesivir in hospitalized patients with COVID-19 and severe renal impairment: experience at a large medical center.Annals of medicine · 2024Article
- A novel nanocomposite drug delivery system for SARS-CoV-2 infections.Nanoscale advances · 2024Article
- COVID-19 therapeutics.Clinical microbiology reviews · 2024Review
- COVID-19: On the threshold of the fifth year. The situation in Spain.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2024Review
- Propensity score matched analysis for the safety and effectiveness of remdesivir in COVID-19 patients with renal impairment.BMC infectious diseases · 2024Article
- Lung Transplantation for Coronavirus Disease-2019 Patients and Coronavirus Disease-2019 in Lung Transplant Recipients.Clinics in chest medicine · 2023Review
- Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease triggered by COVID-19: What is the best practice for treatment?Respiratory medicine case reports · 2023Article
- Remdesivir-Associated Acute Liver Failure in a COVID-19 Patient: A Case Report and Literature Review.Cureus · 2023Article
- Treatment of Severe COVID-19 Infection With Remdesivir in Peritoneal Dialysis.Journal of investigative medicine high impact case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.